Histone deacetylase (HDAC) inhibitors offer a promising strategy for cancer therapy, and the first generation HDAC inhibitors are currently in the clinic. Entirely novel ketone HDAC inhibitors have been developed from the cyclic tetrapeptide apicidin. These compounds show class I subtype selectivity and levels of cellular activity comparable to clinical candidates. A representative example has demonstrated tumor growth inhibition in a human colon HCT-116 carcinoma xenograft model comparable to known inhibitors.
A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo / P. Jones, S. Altamura, R. De Francesco, O.G. Paz, O. Kinzel, G. Mesiti, E. Monteagudo, G. Pescatore, M. Rowley, M. Verdirame, C. Steinkühler. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0022-2623. - 51:8(2008), pp. 2350-2353.
A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo
R. De Francesco;
2008
Abstract
Histone deacetylase (HDAC) inhibitors offer a promising strategy for cancer therapy, and the first generation HDAC inhibitors are currently in the clinic. Entirely novel ketone HDAC inhibitors have been developed from the cyclic tetrapeptide apicidin. These compounds show class I subtype selectivity and levels of cellular activity comparable to clinical candidates. A representative example has demonstrated tumor growth inhibition in a human colon HCT-116 carcinoma xenograft model comparable to known inhibitors.File | Dimensione | Formato | |
---|---|---|---|
Jones et al 2008.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
180.67 kB
Formato
Adobe PDF
|
180.67 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.